- Home
- LVLU vs MRKR Comparison
LVLU vs MRKR Comparison
Compare LVLU & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- MRKR
- Stock Information
- Founded
- LVLU 1996
- MRKR N/A
- Country
- LVLU United States
- MRKR United States
- Employees
- LVLU N/A
- MRKR N/A
- Industry
- LVLU Catalog/Specialty Distribution
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- MRKR Health Care
- Exchange
- LVLU Nasdaq
- MRKR Nasdaq
- Market Cap
- LVLU 12.4M
- MRKR 11.6M
- IPO Year
- LVLU 2021
- MRKR N/A
- Fundamental
- Price
- LVLU $4.97
- MRKR $0.94
- Analyst Decision
- LVLU Hold
- MRKR Strong Buy
- Analyst Count
- LVLU 1
- MRKR 2
- Target Price
- LVLU $15.00
- MRKR $10.25
- AVG Volume (30 Days)
- LVLU 242.1K
- MRKR 149.0K
- Earning Date
- LVLU 11-12-2025
- MRKR 11-13-2025
- Dividend Yield
- LVLU N/A
- MRKR N/A
- EPS Growth
- LVLU N/A
- MRKR N/A
- EPS
- LVLU N/A
- MRKR N/A
- Revenue
- LVLU $285,413,000.00
- MRKR $4,694,988.00
- Revenue This Year
- LVLU N/A
- MRKR N/A
- Revenue Next Year
- LVLU $2.53
- MRKR $9.06
- P/E Ratio
- LVLU N/A
- MRKR N/A
- Revenue Growth
- LVLU N/A
- MRKR N/A
- 52 Week Low
- LVLU $2.98
- MRKR $0.81
- 52 Week High
- LVLU $22.25
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- LVLU 50.32
- MRKR 51.09
- Support Level
- LVLU $4.38
- MRKR $0.87
- Resistance Level
- LVLU $6.16
- MRKR $1.02
- Average True Range (ATR)
- LVLU 0.39
- MRKR 0.06
- MACD
- LVLU 0.04
- MRKR 0.00
- Stochastic Oscillator
- LVLU 27.53
- MRKR 72.17
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.